If you have been reading about nuclear receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
==== Australia ==== Cocaine is a Schedule 8 controlled drug in Australia under the Poisons Standard. It is the second most popular illicit recreational drug in Australia behind cannabis. In Western Australia under the Misuse of Drugs Act 1981, 4.0g of cocaine is the amount of prohibited drugs determining a court of trial, 2.0g is the amount of cocaine required for the presumption of intention to sell or supply, and 28.0g is the amount of cocaine required for purposes of drug trafficking.
Many aspects of the structure-reactivity relationship in organic chemistry can be rationalized through resonance, electron pushing, induction, the eight electron rule, and s-p hybridization, but these are only helpful formalisms and do not represent physical reality. Due to these limitations, a true understanding of physical organic chemistry requires a more rigorous approach grounded in particle physics. Quantum chemistry provides a rigorous theoretical framework capable of predicting the properties of molecules through calculation of a molecule's electronic structure, and it has become a readily available tool in physical organic chemists in the form of popular software packages. The power of quantum chemistry is built on the wave model of the atom, in which the nucleus is a very small, positively charged sphere surrounded by a diffuse electron cloud. Particles are defined by their associated wavefunction, an equation which contains all information associated with that particle. All information about the system is contained in the wavefunction. This information is extracted from the wavefunction through the use of mathematical operators.
A "dry ice bomb" is a balloon-like device using dry ice in a sealed container such as a plastic bottle. Water is usually added to accelerate the sublimation of the dry ice. As the dry ice sublimes, pressure increases, causing the bottle to burst with a loud noise. The screw cap can be replaced with a rubber stopper to make a water rocket. The dry ice bomb device was featured on MythBusters, episode 57 Mentos and Soda, which first aired on August 9, 2006. It was also featured in an episode of Time Warp, as well as in an episode of Archer.
The attitude that Mexico takes in the present eventuality is based on the fact that our determination stems from a need for legitimate defense. We know the limits of our military resources and we know that, given the enormity of the international masses in conflict, our role in the current conflict will not consist of extra-continental war actions, for which we are not prepared. "Simulated neutrality" had been left behind and Mexico was explicitly on the side of the Allies as a belligerent country. Lázaro Cárdenas was appointed Secretary of Defense, the National Military Service (SMN) was created, the United States delivered armaments to improve the capacity of the Mexican army, and the properties of German, Japanese and Italian citizens were seized. Even so, Avila Camacho indicated that Mexico's role in the conflict was not on the battlefield, but to prepare his defenses and provide resources to its new allies. Between June and September 1942 the U-Boats sank four more ships: Tuxpam, Las Choapas, Oaxaca and Amatlán. In view of this situation, the United States, under the pretext of the possibility of aggression by Japan on the coasts of the Pacific Ocean, began discreet negotiations to be allowed to install a military base on the Baja California peninsula; according to historian Humberto Musacchio, that there was speculation that he might have tried to occupy that part of Mexican territory without success.
Founded in 1896 by Fritz Hoffmann-La Roche, the company was known early on for producing various vitamin preparations and derivatives. In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon. During the Second World War, Roche collaborated with the Nazi regime in Germany and used forced labour in its German and Polish-based factories. It also moved all its Jewish employees to the United States to save them from Nazi attention. In 1957, Hoffmann-La Roche introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members). It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid. Originally, it had been intended to create a more efficient drug at combatting tuberculosis. Iproniazid, however, was revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects. In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large dioxin contamination. In 1982, the United States arm of the company acquired Biomedical Reference Laboratories for US$163.5 million. That company dated from the late 1960s, and was located in Burlington, North Carolina. That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc. in Burlington.
Sources: en.wikipedia.org
The consequence of using a single BB in couplings is the formation of a single compound in each bead. The formation of OBOC libraries is an inherent property of the S&P synthesis. The reason is explained in the figure. The structure of the compound formed in a bead depends on the reaction vessels in which the bead happens to occur in the synthetic route. It depends on the decision of the chemist to use the library in the tethered (OBOC) form or cleave down the compounds from the beads and use it as a solution.
== Legal status == In Hong Kong, etorphine is regulated under Schedule 1 of Chapter 134 of the Dangerous Drugs Ordinance. It can be used legally only by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without prescription can be fined HKD$10,000. The penalty for trafficking or manufacturing the substance is a HKD$5,000,000 fine and life imprisonment. Possession for consumption without licence from the Department of Health is illegal, with a HKD$1,000,000 fine and/or 7 years of jail time. In the Netherlands etorphine is a Schedule I drug of the Opium Law. It is used only for veterinary purposes in zoos to immobilise large animals. In the United States etorphine is listed as a Schedule I (i.e. as not having any legal use) drug with an ACSCN of 9056, although its hydrochloride salt is classified as Schedule II (i.e. as having a legal use, such as tranquilization of large animals) with an ACSCN of 9059. In the United Kingdom, under the Misuse of Drugs Act 1971, etorphine is controlled as a Class A substance. In Italy etorphine is illegal, as are the parent compounds Dihydroetorphine and Acetorphine. (Data from 2022)
Biden was a strong supporter of the War in Afghanistan, saying, "Whatever it takes, we should do it." As head of the Senate Foreign Relations Committee, he said in 2002 that Iraqi president Saddam Hussein was a threat to national security and there was no other option than to "eliminate" that threat. In October 2002, he voted in favor of the Authorization for Use of Military Force Against Iraq, approving the U.S. invasion of Iraq. As chair of the committee, he assembled witnesses to testify in favor of the authorization. They gave testimony grossly misrepresenting the intent, history, and status of Saddam and his government, and touted Iraq's fictional possession of weapons of mass destruction. Biden eventually became a critic of the war, calling his vote a "mistake" by 2005, but did not push for withdrawal. He supported the appropriations for the occupation, but argued that the war should be internationalized, that more soldiers were needed, and that the Bush administration should "level with the American people" about its cost and length. By late 2006, Biden's stance had shifted considerably. He opposed the troop surge of 2007, saying General David Petraeus was "dead, flat wrong" in believing the surge could work. Biden, through a plan developed with Council on Foreign Relations president Leslie H. Gelb, instead advocated dividing Iraq into a loose federation of three ethnic states. In September 2007, a non-binding resolution endorsing the plan passed the Senate, but the idea failed to gain traction.
==== First-episode psychosis ==== First-episode psychosis (FEP) is the first time that psychotic symptoms are presented. NICE recommends that all people presenting with first-episode psychosis be treated with both an antipsychotic drug and cognitive behavioral therapy (CBT). NICE further recommends that those expressing a preference for CBT alone be informed that combination treatment is more effective. A diagnosis of schizophrenia is not made at this time as it takes longer to be determined by both DSM-5 and ICD-11, and only around 60% of those presenting with a first episode of psychosis will later be diagnosed with schizophrenia. The conversion rate for a first episode of drug induced psychosis to bipolar disorder or schizophrenia is lower, with 30% of people converting to either bipolar disorder or schizophrenia. NICE makes no distinction between substance-induced psychosis and any other form of psychosis. The rate of conversion differs for different classes of drugs. Pharmacological options for the specific treatment of FEP have been discussed in recent reviews. The goals of treatment for FEP include reducing symptoms and potentially improving long-term treatment outcomes. Randomized clinical trials have provided evidence for the efficacy of antipsychotic drugs in achieving the former goal, with first-generation and second generation antipsychotics showing about equal efficacy. The evidence that early treatment has a favorable effect on long-term outcomes is equivocal.
== Management == There is currently no cure for PFBC nor a standard course of treatment. The available treatment is directed symptomatic control. If parkinsonian features develop, there is generally poor response to levodopa therapy. Case reports have suggested that haloperidol or lithium carbonate may help with psychotic symptoms. One case report described an improvement with the use of a bisphosphonate.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.